News & Updates

Beyond 1 year, the humanized monoclonal antibody mepolizumab maintained real-world efficacy and safety in patients with severe eosinophilic asthma in the REALITI-A cohort study, reports an expert at ERS 2021.

Adding cyclophosphamide to glucocorticoid treatment in patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) was associated with a numerically increased risk of mortality, according to results of the phase III EXAFIP trial.

What used to be a place that holds a perception of relative safety and minimal health risk to its occupants, the office now appears to be a place that is inching its way towards the other side of the respiratory health spectrum, with office-related occupational asthma on the rise, according to findings from a UK cross-sectional study presented at ERS 2021.

Treatment with MV130, a sublingual bacterial immunotherapy, reduces the number of exacerbations in patients with chronic obstructive pulmonary disease (COPD), according to a recent study presented at ERS 2021.

Daily treatment with doxycycline did not shorten recovery time or reduce hospitalization or death in community-dwelling older adults with COVID-19, according to a study from the PRINCIPLE Collaborative Group.